Cel­lec­tis signs $760M mile­stone deal with NK up­start; Im­muno­core brings on As­traZeneca vet to shep­herd bis­pe­cif­ic launch plans

Af­ter near­ly two decades as of­ten one of the on­ly com­pa­nies de­vel­op­ing off-the-shelf CAR-Ts, Cel­lec­tis has in re­cent years racked up big-name part­ner­ships, in­clud­ing with Arie Bellde­grun’s Al­lo­gene and French gi­ant Servi­er.

Now they’ve teamed with a lit­tle known start­up that has yet to an­nounce a Se­ries A: New York-based Cy­tovia Ther­a­peu­tics. The two com­pa­nies an­nounced on Tues­day a deal to de­vel­op uni­ver­sal gene-edit­ed nat­ur­al killer cells and CAR-NK cells for sol­id tu­mors and oth­er can­cers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER